[1]
|
H. Seyednejad, M. Imani, T. Jamieson and A. M. Seifalian, “Topical Haemostatic Agents,” British Journal of Surgery, Vol. 95, No. 10, 2008, pp. 1197-1225.
doi:10.1002/bjs.6357
|
[2]
|
G. J. Murphy, B. C. Reeves, C. A. Rogers, S. I. Rizvi, L. Culliford and G. D. Angelini, “Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery,” Circulation, Vol. 116, No. 22, 2007, pp. 2544-2552.
doi:10.1161/CIRCULATIONAHA.107.698977
|
[3]
|
A. Shander, “Financial and Clinical Outcomes Associated with Surgical Bleeding Complications,” Surgery, Vol. 142, Suppl. 4, 2007, pp. S20-S25.
doi:10.1016/j.surg.2007.06.025
|
[4]
|
M. Leixnering, J. Reichetseder, A. Schultz, M. Figl, E. Wassermann, H. Thurnher and H. Redl, “Gelatine Thrombin Granules For Hemostasis in a Severe Traumatic Liver and Spleen Rupture Model in Swine,” Journal of Trauma-Injury Infection & Critical Care, Vol. 64, No. 2, 2008, pp. 456-461. doi:10.1097/TA.0b013e3180340de1
|
[5]
|
M. C. Oz, D. M. Cosgrove, B. R. Badduke, J. D. Hill, M. R. Flannery, R. Palumbo and N. Topic, “Controlled Clinical Trial of a Novel Hemostatic Agent in Cardiac Surgery. The Fusion Matrix Study Group,” The Annals of Thoracic Surgery, Vol. 69, No. 5, 2000, pp. 1376-1382.
doi:10.1016/S0003-4975(00)01194-2
|
[6]
|
R. A. De la Torre, S. L. Bachman, A. A. Wheeler, K. N. Bartow and J. S. Scott, “Hemostasis and Hemostatic Agents in Minimally Invasive Surgery,” Surgery, Vol. 142, No. 4, 2007, pp. S39-S45.
doi:10.1016/j.surg.2007.06.023
|
[7]
|
Baxter Healthcare SA, “Floseal Instructions for Use,” Zurich.
|
[8]
|
S. Samadrula, “Topical Hemostatic Agents in Surgery: A Surgeon’s Perspective,” AORN Journal, Vol. 88, No. 3, 2008, pp. S2-S11. doi:10.1016/S0001-2092(08)00586-3
|